Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
A new research paper reframes the simulation hypothesis, asking whether reality could be simulated and what science can test.
Leveraging modular gene editors and new regulatory pathways, Aurora will develop and commercialize therapies that can be rapidly tailored to many rare variants -- Founded by CRISPR pioneers Jennifer ...
Since the 2000s, Google Search—and later YouTube and Discover—served as the primary discovery and monetization engines for digital publishing. This relationship was symbiotic, if lopsided. Two decades ...
Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...
Abstract: Path coverage is of critical importance in software testing and verification. Furthermore, path explosion is a well-known challenge for automatic software analysis techniques like symbolic ...
Abstract: Indirect tyre pressure monitoring system (ITPMS) can effectively reduce tyre blowouts risk and enhance high-speed vehicle operation safety, gradually emerging as a rapidly popular-ized ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
The market is rapidly transitioning from episodic diagnostics to continuous health monitoring. By 2035, the integration of ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...
Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback